EA000626B3 - Синергические комбинации зидовудина, 1592u89 и зтс или ftc - Google Patents

Синергические комбинации зидовудина, 1592u89 и зтс или ftc

Info

Publication number
EA000626B3
EA000626B3 EA199700203A EA199700203A EA000626B3 EA 000626 B3 EA000626 B3 EA 000626B3 EA 199700203 A EA199700203 A EA 199700203A EA 199700203 A EA199700203 A EA 199700203A EA 000626 B3 EA000626 B3 EA 000626B3
Authority
EA
Eurasian Patent Office
Prior art keywords
cis
amino
oxathiolan
pyrimidin
hydroxymethyl
Prior art date
Application number
EA199700203A
Other languages
English (en)
Russian (ru)
Other versions
EA199700203A1 (ru
EA000626B1 (ru
Inventor
Дейвид Уолтер Бэрри
Марта Хайдер Сейнт-Клэр
Original Assignee
ВАЙВ ХЕЛТКЕР ЮКей ЛИМИТЕД
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA000626(B3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Application filed by ВАЙВ ХЕЛТКЕР ЮКей ЛИМИТЕД filed Critical ВАЙВ ХЕЛТКЕР ЮКей ЛИМИТЕД
Publication of EA199700203A1 publication Critical patent/EA199700203A1/ru
Publication of EA000626B1 publication Critical patent/EA000626B1/ru
Publication of EA000626B3 publication Critical patent/EA000626B3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
EA199700203A 1995-03-30 1996-03-28 Синергические комбинации зидовудина, 1592u89 и зтс или ftc EA000626B3 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
PCT/EP1996/001352 WO1996030025A1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc

Publications (3)

Publication Number Publication Date
EA199700203A1 EA199700203A1 (ru) 1998-02-26
EA000626B1 EA000626B1 (ru) 1999-12-29
EA000626B3 true EA000626B3 (ru) 2016-04-29

Family

ID=26306774

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199700203A EA000626B3 (ru) 1995-03-30 1996-03-28 Синергические комбинации зидовудина, 1592u89 и зтс или ftc

Country Status (35)

Country Link
US (1) US6417191B1 (en:Method)
EP (1) EP0817637B1 (en:Method)
JP (1) JP2954357B2 (en:Method)
KR (1) KR100542536B1 (en:Method)
CN (1) CN1103593C (en:Method)
AP (1) AP652A (en:Method)
AT (1) ATE220551T1 (en:Method)
AU (1) AU715213B2 (en:Method)
BR (3) BRPI9607851B8 (en:Method)
CA (1) CA2216634C (en:Method)
CZ (1) CZ295940B6 (en:Method)
DE (3) DE69622386T2 (en:Method)
DK (1) DK0817637T3 (en:Method)
EA (1) EA000626B3 (en:Method)
EE (1) EE04047B1 (en:Method)
ES (1) ES2179193T3 (en:Method)
FR (1) FR05C0022I2 (en:Method)
GE (1) GEP20022647B (en:Method)
HU (1) HU224010B1 (en:Method)
IL (1) IL117727A (en:Method)
LU (1) LU91171I2 (en:Method)
MX (1) MX9707316A (en:Method)
MY (1) MY115461A (en:Method)
NL (1) NL300195I2 (en:Method)
NO (2) NO313787B1 (en:Method)
NZ (1) NZ306419A (en:Method)
OA (1) OA10616A (en:Method)
PL (1) PL187085B1 (en:Method)
PT (1) PT817637E (en:Method)
RO (1) RO117995B1 (en:Method)
SI (1) SI0817637T1 (en:Method)
SK (1) SK283825B6 (en:Method)
TR (1) TR199701074T1 (en:Method)
UA (1) UA60293C2 (en:Method)
WO (1) WO1996030025A1 (en:Method)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049411A1 (en) 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
BR9809127A (pt) * 1997-05-17 2000-08-01 Glaxo Group Ltd Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
CA2374198A1 (en) * 1998-05-29 1999-12-02 Maki Arai Combination therapy for treatment of fiv infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
AR040242A1 (es) * 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
EA015145B1 (ru) 2003-01-14 2011-06-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции
KR20050119652A (ko) 2003-03-24 2005-12-21 에프. 호프만-라 로슈 아게 역전사 효소 저해제로서의 벤질-피리다진온
DE602004030369D1 (de) 2003-10-24 2011-01-13 Immunaid Pty Ltd Therapieverfahren
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP1940781A1 (en) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
MX2009005881A (es) 2006-12-13 2009-06-12 Hoffmann La Roche Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
JP5467870B2 (ja) * 2007-02-09 2014-04-09 アルファファーム ピーティーワイ リミテッド 異なる物理的形態の２種以上の有効医薬成分を含有する投薬形態
PL2435825T3 (pl) 2009-05-27 2015-12-31 Biotempus Ltd Sposoby leczenia chorób
UA105556C2 (uk) 2010-01-27 2014-05-26 Віів Гелскер Компані Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
HK1220390A1 (zh) 2013-08-29 2017-05-05 Teva Pharmaceutical Industries Ltd. 包括恩曲他滨，替诺福韦，达芦那韦和利托那韦的单位剂型以及包含达芦那韦和利托那韦的单体片剂
EP3129009A1 (en) 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
CN117164657A (zh) 2014-08-12 2023-12-05 莫纳什大学 定向淋巴的前药
EP3347340A4 (en) 2015-09-08 2019-01-23 Monash University LYMPHENLEITUNGSPRODRUGS
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
WO2019046491A1 (en) * 2017-08-29 2019-03-07 Ariya Therapeutics, Inc. LIPIDIC PRODRUGS DIRECTING TO THE LYMPHATIC SYSTEM
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
AU2021217172A1 (en) 2020-02-05 2022-09-22 Monash University Lipid prodrugs of neurosteroids

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015309A1 (en) * 1991-03-06 1992-09-17 The Wellcome Foundation Limited Antiviral nucleoside combination
EP0513917A1 (en) * 1991-05-16 1992-11-19 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
WO1993023021A2 (en) * 1992-05-13 1993-11-25 The Wellcome Foundation Limited Therapeutic combinations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
ATE230267T1 (de) 1996-06-25 2003-01-15 Glaxo Group Ltd Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv
WO1997049411A1 (en) 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
DE10226522A1 (de) * 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015309A1 (en) * 1991-03-06 1992-09-17 The Wellcome Foundation Limited Antiviral nucleoside combination
EP0513917A1 (en) * 1991-05-16 1992-11-19 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
WO1993023021A2 (en) * 1992-05-13 1993-11-25 The Wellcome Foundation Limited Therapeutic combinations

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANTIMICROB AGENTS CHEMOTHER, 37 (10). 1993. 2206-2211., XP000578786, MATHEZ D. ET AL.: "INFECTIOUS AMPLIFICATION OF WILD-TYPE HUMAN IMMUNODEFICIENCY VIRUS FROM PATIENTS' LYMPHOCYTES AND MODULATION BY REVERSE TRANSCRIPTASE INHIBITORS IN-VITRO", see abstract, see page 2210, column 2, paragraph 4 - page 2211, column 1, paragraph 1 *
PROC NATL ACAD SCI USA, 90 (12). 1993. 5653-5656., XP000578149, TISDALE M. ET AL.: "RAPID IN-VITRO SELECTION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 RESISTANT TO 3' THIACYTIDINE INHIBITORS DUE TO A MUTATION IN THE YMDD REGION OF REVERSE TRANSCRIPTASE", see page 5654, column 2, paragraph 4 *
PROGRAM ABSTR INTERSCI CONF ANTIMICROB AGENTS CHEMOTHER, OCT 4-7 1994, P7, XP000579331, DALUGE S.M. ET AL.: "1592U89 succinate - a novel carbocyclic nucleoside analogue with potent, selective anti-HIV activity." see the whole document *
PROGRAM ABSTR INTERSCI CONF ANTIMICROB AGENTS CHEMOTHER, OCT 4-7 1994, P92, XP000579330, TISDALE M. ET AL.: "Anti-HIV activity of (1S,4R)-4[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (159U89)", see the whole document *
SCRIP WORLD PHARMACEUTICAL NEWS. NO. 1969, OCT 25, 1994, XP000578818, "New AIDS therapies at ICAAC; Triple therapy Fusion toxins Wellcome's 1592U89 Protease inhibitor prodrugs", see page 26, column 2, paragraph 2 *

Also Published As

Publication number Publication date
ATE220551T1 (de) 2002-08-15
CN1103593C (zh) 2003-03-26
JP2954357B2 (ja) 1999-09-27
NL300195I1 (nl) 2005-08-01
TR199701074T1 (xx) 1998-02-21
CA2216634C (en) 2004-07-20
CN1185110A (zh) 1998-06-17
AP9701089A0 (en) 1997-10-31
IL117727A0 (en) 1996-07-23
GEP20022647B (en) 2002-03-25
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
IL117727A (en) 1999-11-30
MX9707316A (es) 1997-11-29
SK283825B6 (sk) 2004-02-03
WO1996030025A1 (en) 1996-10-03
JPH10511682A (ja) 1998-11-10
HUP9801571A3 (en) 2001-04-28
EP0817637B1 (en) 2002-07-17
BRPI9612992B1 (pt) 2020-08-04
EP0817637A1 (en) 1998-01-14
DE69622386T2 (de) 2003-02-13
NO313787B1 (no) 2002-12-02
FR05C0022I2 (en:Method) 2005-10-21
SI0817637T1 (en) 2002-10-31
EA199700203A1 (ru) 1998-02-26
AU5497296A (en) 1996-10-16
OA10616A (en) 2001-03-15
AP652A (en) 1998-06-19
KR100542536B1 (ko) 2006-03-23
DE122005000029I1 (de) 2005-10-06
PL187085B1 (pl) 2004-05-31
BR9607851A (pt) 1998-07-21
BR9607851B1 (pt) 2009-01-13
DK0817637T3 (da) 2002-11-11
CZ295940B6 (cs) 2005-12-14
EA000626B1 (ru) 1999-12-29
UA60293C2 (uk) 2003-10-15
HU224010B1 (hu) 2005-04-28
ES2179193T3 (es) 2003-01-16
NO2005014I1 (no) 2005-06-06
FR05C0022I1 (en:Method) 2005-06-10
NO2005014I2 (no) 2008-02-11
MY115461A (en) 2003-06-30
LU91171I9 (en:Method) 2018-12-28
LU91171I2 (fr) 2005-07-04
NO974510D0 (no) 1997-09-29
BRPI9607851B8 (pt) 2019-11-05
KR19980703420A (ko) 1998-11-05
AU715213B2 (en) 2000-01-20
CA2216634A1 (en) 1996-10-03
CZ309097A3 (cs) 1998-05-13
RO117995B1 (ro) 2002-12-30
PL322532A1 (en) 1998-02-02
US6417191B1 (en) 2002-07-09
HK1009401A1 (en) 1999-09-10
SK129597A3 (en) 1998-07-08
DE122005000029I2 (de) 2006-04-27
HUP9801571A2 (hu) 1999-01-28
NO974510L (no) 1997-09-29
EE04047B1 (et) 2003-06-16
EE9700240A (et) 1998-04-15
NL300195I2 (nl) 2005-11-01
DE69622386D1 (de) 2002-08-22

Similar Documents

Publication Publication Date Title
BRPI9607851B8 (pt) combinação e formulação farmacêutica.
ES2377066T3 (es) Composición terapéutica que contiene al menos un derivado de la pirrobenzodiacepina y la fludarabina
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
BR0314236A (pt) Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
JPH0125A (ja) ｄｓＲＮＡと逆転写酵素インヒビターを含んで成るＨＩＶ感染治療のための医薬組成物
EP4442321A3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
CA2225788A1 (en) Therapeutic agents and autoimmune diseases
Mannis et al. Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia
BR9808060A (pt) Composição farmacêutica, processos para tratamento de infecções virais pela administração de uma quantidade farmaceuticamente segura e eficaz de uma composição farmacêutica, uso da lamivudina ou um seu derivado farmaceuticamente aceitável, e, processo para a preparação de uma composição farmacêutica.
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
AR040242A1 (es) Composiciones farmaceuticas
BRPI0415322A (pt) composição farmacêutica antiretroviral, processo para a preparação de uma composição farmacêutica antiretroviral, método para reduzir a carga de consumo de pìlulas para um paciente, método para aumentar a meia-vida in vivo de lamivudina e de zidovudina enquanto não afetando a meia-vida de nevirapina
ES2678122T3 (es) Comprimidos bucales mucoadherentes para el tratamiento del herpes orofacial
WO2004028457A3 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF HIV gp41-DERIVED PEPTIDES, AND ITS USE IN THERAPY
BR9809127A (pt) Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente
DE50202865D1 (de) Herstellung reiner stereoisomere von tricyclo-[5.2.1.0(2.6) ]-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
ES2189964T3 (es) Combinaciones que comprenden vx478, zidovudina, y 1592u89 para uso en el tratamiento de infecciones por vih.
EA200300430A1 (ru) Новые фармацевтические композиции, содержащие эпинастин и псевдоэфедрин
TH28828A (th) สิ่งผสมรวมซึ่งเสริมฤทธิ์กันของไซโดวูดีน 1592u89 และ 3tc
TH20892B (th) สิ่งผสมรวมซึ่งเสริมฤทธิ์กันของไซโดวูดีน 1592u89 และ 3tc
BR9809124A (pt) Combinação, formulação, farmacêutica, processo para o tratamento de uma infecção por hiv em um animal, infectado, uso de (-)-(1s, 4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-cicl openteno-1-metanol, e, pacote de paciente
RU2005138167A (ru) Противовирусное средство (варианты) и способ лечения на его основе
CA2583195A1 (en) Method for treating hiv infection through co-administration of tipranavir and reverset
TH34798A (th) การรวมสารต้านไวรัส
AR007615A1 (es) Combinaciones antivirales, formulaciones conteniendo las mismas, uso de los mismos en la manufactura de medicamentos y un articulo que los contiene.

Legal Events

Date Code Title Description
ND4A Extension of term of a eurasian patent

Designated state(s): RU

PC4A Registration of transfer of a eurasian patent by assignment
LD4A Eurasian patent limited on request of patent holder (b3)
TK4A Corrections in published eurasian patents
ND4A Extension of term of a eurasian patent
MK4A Patent expired

Designated state(s): AM KZ KG MD TJ TM

MK4A Patent expired

Designated state(s): AZ

MK4A Patent expired

Designated state(s): BY RU